Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Cancer treatments often cause skin, nail, and hair problems.

PPX causes much less hair loss than traditional taxanes.

Targeting multiple pathways and understanding genetic mutations are crucial for effective melanoma therapy.

Lower doses of topotecan are safe for eyes, but higher doses may harm the retina.

The FDA approved a new Pfizer drug for hair loss in teens.

The buffy coat method yields higher TGF-β1 levels in PRP, especially in males.

Oral tofacitinib successfully treated a girl's severe skin and hair conditions.

Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.

A rare scalp tumor was removed from a 49-year-old woman, with a good outlook if benign but needing careful monitoring if malignant.

Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

Protoporphyrin IX is useful in cancer treatment but can cause health problems if not properly regulated.

Upadacitinib improved multiple immune-related conditions in one patient.

ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.

Some IBD patients on anti-TNFs developed severe skin issues, but ustekinumab helped.

Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.

Ki-67 levels do not predict treatment response in triple-negative breast cancer.

Dutasteride potentially improves cell survival and reduces retinal damage in retinitis pigmentosa.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Upadacitinib effectively treats psoriasiform eczema and some related conditions.

CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.

P311 helps skin stem cells become myofibroblast-like cells, aiding wound healing.

Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.

Nephronectin is linked to worse breast cancer outcomes and helps cancer spread.

Topical tofacitinib shows promise as a future treatment for alopecia areata.

TPO antibodies can help identify hypothyroid patients who still have symptoms despite normal TSH levels.